Introduction
============

As one of the most common cancers in women worldwide and despite the advances in cancer research and therapy, breast cancer remains a highly lethal malignant disease that represents a heavy burden to public health. The recommended treatment according to the molecular subtypes acknowledged by the St. Gallen consensus has shown favorable effects on patients' survival.[@b1-bctt-10-161] However, the description of new associated molecules and the understanding of the mechanisms involved in the development of the disease will allow us to make a better prediction of the disease prognosis and possibly increase the accuracy in determining treatment subgroups based on novel targets able to improve the survival rates.

Advances have been made to propose treatment alternatives and specific drug targets for estrogen receptor (ER) alpha-positive, progesterone receptor (PR)-positive, and human epidermal growth factor receptor 2 (HER2)-positive breast cancers, whereas the most malignant triple-negative breast cancer phenotype, associated with higher rates of recurrence, metastasis, and worse prognosis,[@b1-bctt-10-161] still has limited treatment choices.

Chronic inflammation has been revisited as an important risk factor associated with tumor progression.[@b2-bctt-10-161] The progression of malignant tumors is reinforced by various molecules that are secreted during inflammation such as growth factors and cytokines that are common to immunological reactions and other inflammation phenomena. The molecules secreted by tumor cells contribute to develop their own microenvironment, modifying the extracellular matrix that surrounds them and the number of sensory neurons and modulating the immune system surveillance.[@b3-bctt-10-161],[@b4-bctt-10-161] These events protect the tumors of immune regulatory signals, favoring their growth and invasion,[@b3-bctt-10-161] rendering the factors involved in these chronic inflammatory processes potential therapeutic targets for cancer.

The vanilloid family of transient receptor potential (TRP) channels consists of a broad variety of nonselective cation channels that integrate environmental and physico-chemical signals for dynamic homeostatic control. This family of TRP channels may be activated by multiple pain-inducing stimuli including inflammatory conditions such as low pH (\<6.0) and high temperature (37°C--42°C) and chemicals such as capsaicin, anandamide, and inflammatory lipoxygenase metabolites.[@b5-bctt-10-161] Additionally, the activation of TRPV family and other TRP channels has been involved in homeostasis of calcium, associated with inflammation, proliferation, angiogenesis, and regulation of cell death in tumors.[@b6-bctt-10-161],[@b7-bctt-10-161]

Recent studies have reported the important role of TRP channels in an increasing number of diseases, TRPV1 being one of the most studied members of vanilloid family, which have been related to modulation of breast cancer cell death.[@b8-bctt-10-161]--[@b10-bctt-10-161] The activation of TRPV1 in MCF-7 cells by its classical agonist capsaicin alone or in combination with other modulators such as MRS1477 and the chemotherapeutical agent cisplatin against breast cancer appears to contribute to induce cell death by apoptosis with mitochondrial membrane depolarization, production of ROS, and activation of caspases 3 and 9.[@b11-bctt-10-161],[@b12-bctt-10-161]

Current evidence shows that low doses of capsaicin may induce apoptosis in tumor cells, while higher doses of capsaicin activate necrosis. This is dependent on the cell lineage and physiological context; for instance, in Hela cells with overexpression of TRPV1, nanomolar concentration of capsaicin induces a transitory calcium signal mediated by TRPV1 without any toxic effect, whereas micromolar concentration (1--10 µM) of capsaicin induces apoptotic cell death and with doses as high as 100 µM cell death follows a necrotic pattern.[@b6-bctt-10-161]

This special pattern of response of the channel to increasing doses of capsaicin may be very relevant in the context of advanced breast cancer tumors, where the overexpressing TRPV1 sensory neurons exhibit aberrant collateral axonal branching.[@b4-bctt-10-161] The utilization of capsaicin in this context could reduce the aberrant activity of sensory neurons by blocking the tumor growth and, concomitantly, the pain sensation.[@b4-bctt-10-161],[@b10-bctt-10-161] Finding the minimum concentration necessary to induce cell death without causing excessive pain or inflammation can thus be considered as an important constraint to assess treatment efficacy of TRPV1 activators.[@b10-bctt-10-161]

Another clinically relevant characteristic of TRPV1 is their modulation by estrogens.[@b13-bctt-10-161],[@b14-bctt-10-161] The available evidence suggest that 17β-estradiol is the only steroid that enhances the activity of TRPV1 channel.[@b15-bctt-10-161],[@b16-bctt-10-161] In addition, 17β-estradiol exerts classical genomic effects increasing the expression of TRPV1 in uterine afferent neurons[@b17-bctt-10-161] as well as in dorsal root ganglion cells via mechanisms dependent on ERα and ERβ with effects on the nociception mediated by primary afferent neurons.[@b17-bctt-10-161],[@b18-bctt-10-161]

All these new evidence pointed out the importance of understanding the role of TRPV1 in the progression of breast cancer and aroused enthusiasm among researchers on the way of a new potential target for treatment. However, until now, most of the evidence have emerged mainly from in vitro models, and the role of the channel in vivo remains to be elucidated. For the best of our knowledge, the possible effect of estrogens on the expression and function of TRPV1 in human breast cancer has not been reported, although understanding this mechanism could be of special interest given the strict estrogen dependence of the malignancy of these tumor cells as indicated by St. Gallen Consensus.[@b1-bctt-10-161]

To explore a possible role of TRPV1 channel in human breast cancer, first, we determined the expression and patterns of subcellular distribution of TRPV1 in two breast cancer cell lines with different malignant potentials such as MCF-7 and MDA. Second, we verified the dose--effect of estrogens on the expression of TRPV1 in both cell lines and the dependence of this effect on ERs. Finally, we assessed the expression and localization patterns of TRPV1 in human breast carcinomas and their correlation with survival. We tested the association of the expression patterns of TRPV1 with the molecular subtypes of the St. Gallen Consensus.[@b1-bctt-10-161]

Materials and methods
=====================

Tissue samples and survival record
----------------------------------

A total of 33 paraffin-embedded tissue blocks, corresponding to mastectomies with invasive breast carcinomas, were collected from the Pathology Department at Carlos van Buren Hospital (January 1, 2010--June 30, 2012). The survival was determined at 5 years of follow-up, from medical records and the national register of death causes (one case was not considered in the analysis of survival due to lack of information about the cause of death). The study was approved by the Ethics Committee for Human Studies of the Carlos van Buren Hospital. All patients signed a written informed consent authorizing the use of their samples and the associated data in biomedical research purposes.

Tissue microarray (TMA)
-----------------------

Representative tumor areas were selected on H&E-stained sections, and the slides were then overlaid on the original paraffin block. TMAs were constructed using a manual tissue arrayer (Sakura Co., Tokyo, Japan), with one representative cylindrical core of 3.0 mm diameter taken from each original tissue block and then arranged into a recipient of paraffin block. Samples of normal breast tissue were inserted in each recipient block as controls. A map specifying the exact position of each case was prepared to facilitate the interpretation of the immunohistochemical results.

Immunohistochemistry and immunofluorescence
-------------------------------------------

Primary antibodies for TRPV1 (1:1,000; Abcam, Cambridge, MA, USA), ER (RTU; Dako), PR (RTU; Dako, Agilent, Santa Clara, CA, USA), HER2 (RTU; Dako), and Ki67 (RTU; Dako) were used. The tumor samples were fixed with 10% formalin for 12 hours before processing. The TMA was cut obtaining slices of 4 µm thick. The immunohistochemical stain was performed with Dako Autostainer Link 48 using the EnVision FLEX system. Primary and secondary antibodies were incubated for 20 minutes. The EnVision FLEX chromogen DAB was incubated for 5 minutes. The slides were counterstained with Harris hematoxylin for 1 minute. We used mouse testis and cerebral vascular endothelium as controls for TRPV1 expression. To increase the robustness in detection of TRPV1, we used immunofluorescence techniques with two different antibodies directed at the terminal amino and carboxyl portions of the channel (C-TRPV1 and N-TRPV1, 1:1,000; Abcam) and Golgi-GFP imaging in MDA cells.

Mapping of the subcellular distribution of TRPV1 channel
--------------------------------------------------------

We utilized two fluorescent probes for detection of endoplasmic reticulum and Golgi complex and examined the colocalization with the channel signal applying an automated procedure ([Figure 1B](#f1-bctt-10-161){ref-type="fig"}). The colocalization analysis identifies the spatial position where two or more digitalized stain signals converge. Finally, we generated four digital subcellular masks that identify the position of plasma membrane, cytoplasm, nucleus, and perinuclear region to easily distinguish the main cellular compartments where the channel could be distributed.

Statistical analyses
--------------------

Statistical tests were performed using StatGraphics 5.1, 12.0 and SigmaPlot OriginPro 8.05 with ANOVA to determine statistical significance and multiple comparison procedure (Fisher's exact test for minimum statistical difference) with a confidence level of 95% to determine the pair of data that produces the difference. The statistical association of classical and nonclassical patterns of TRPV1 expression with the molecular St. Gallen subtypes LA, LB, HER2, and triple negative was examined with Fisher's exact test. We determined the association between categories of TRPV1 and survival with the Kaplan--Meyer model using the log-rank test at 5 years follow-up.

Results
=======

The clinicopathological data of patients included in the study according to the categories of TRPV1 expression are described in [Table 1](#t1-bctt-10-161){ref-type="table"}.

Estrogen-dependent expression and subcellular distribution of TRPV1 in breast cancer cell lines
-----------------------------------------------------------------------------------------------

Real-time PCR confirmed TRPV1 mRNA expression in both MCF-7 and MDA-MB-231 cell lines ([Figure 1A](#f1-bctt-10-161){ref-type="fig"}). In addition, immunofluorescence detection confirmed the expression of TRPV1 protein in MCF-7 and also in MDA-MB-231 ([Figure 1B](#f1-bctt-10-161){ref-type="fig"}). MCF-7 and MDA-MB-231 exhibited different subcellular distribution patterns. In the case of MCF-7, a high Pearson coefficient value was obtained in membrane and cytoplasm, indicating that the expression of the channel was concentrated in these compartments, similar to the current channel distribution in several tissues normally expressing TRPV1 ([Figure 1B and C](#f1-bctt-10-161){ref-type="fig"}).[@b5-bctt-10-161] In the case of MDA-MB-231, the expression was predominant at the endoplasmic reticulum, Golgi, and perinuclear region ([Figure 1B and C](#f1-bctt-10-161){ref-type="fig"}).

qPCR experiments to measure the level of mRNA of ERs did not show any difference in the amount of mRNA ([Figure 1D](#f1-bctt-10-161){ref-type="fig"}) between MCF-7 and MDA-MB-231 cell lines. However, MDA-MB-231 and MCF-7 exhibited different expressions of ER subtypes. Although ERβ was present in both cell lines, only MCF-7 expressed ERα (*P*\<0.05; [Figure 1D](#f1-bctt-10-161){ref-type="fig"}) indicating, as already suggested, that MDA-MB-231 is associated with a more malignant phenotype.

The response curve of TRPV1 at different doses of 17β-estradiol showed an increase in TRPV1 mRNA expression only in MCF-7 cells ([Figure 1E](#f1-bctt-10-161){ref-type="fig"}). Notably, this effect was completely reverted by the inhibitor of ERs α and β ICI 182780, suggesting that the channel expression was due to classical 17β-estradiol genomic effect that was dependent on ERα. These results are summarized in [Figure 1E](#f1-bctt-10-161){ref-type="fig"}, indicating that TRPV1 is expressed in both cell lines but the estrogen-induced expression pattern of TRPV1 changes, probably depending on the malignancy of the tumor. [Figure 1F](#f1-bctt-10-161){ref-type="fig"} summarizes the parameters that describe the cellular model of breast cancer according to the degree of malignancy, adding the expression pattern of TRPV1.

TRPV1 expression and subcellular distribution in human breast cancer samples
----------------------------------------------------------------------------

The immunofluorescence of C-TRPV1 and N-TRPV1 antibodies matched with the immunohistochemical results, confirming the positive and negative results of TRPV1 expression. Immunofluorescence was unable to detect a well-defined expression pattern of the channel, but it was useful to demonstrate that the perinuclear expression corresponds to the presence of the channel at the ER/Golgi complex ([Figure 1A](#f1-bctt-10-161){ref-type="fig"}). The immunohistochemical assays revealed distinctive patterns of subcellular localization of TRPV1 in breast cancer samples. Among the specimens expressing TRPV1, we identified the following: 1) An intracellular diffuse pattern that was similar to the pattern of TRPV1 expression found in control tissues, as the epithelial cells in healthy breast (acini and ducts), mice seminiferous tubules, and capillary endothelium in brain tissue (data not shown). This pattern corresponded to the classical category. 2) A pattern in aggregates at the ER/Golgi. 3) A group that, in addition to TRPV1 aggregates at the ER/Golgi, exhibited a relatively diffuse distribution of TRPV1 in the cytosol. These two last forms of presentation were grouped as the "nonclassical" category ([Figure 2A and B](#f2-bctt-10-161){ref-type="fig"}). TRPV1 expression was undetectable in two specimens, which were included in the classical category. In all, 21 cases were classified as classical and 12 cases were classified as nonclassical category ([Figure 2C](#f2-bctt-10-161){ref-type="fig"}). The classical pattern of TRPV1 was mainly observed in low-grade St. Gallen groups, while the nonclassical pattern of TRPV1 was observed in more aggressive St. Gallen groups (*P*\<0.05; [Table 1](#t1-bctt-10-161){ref-type="table"} and [Figure 2C](#f2-bctt-10-161){ref-type="fig"}). The Kaplan--Meyer survival curves indicate better prognosis in patients with the classical pattern of immunohistochemical expression of TRPV1 (log-rank test \<0.05; [Figure 2D](#f2-bctt-10-161){ref-type="fig"}).

Discussion
==========

Currently located at the plasma membrane, TRPV1 nonselective cation channel is especially permeable to Na^+^ and Ca[@b2-bctt-10-161]^+^. Various stimuli such as capsaicin, heat, acid pH, endogenous lipids, and some inflammatory mediators may activate this channel, which is considered a permanent and fast controller of the cellular homeostasis.[@b19-bctt-10-161],[@b20-bctt-10-161] In the nervous system, TRPV1 is constitutively expressed mainly in neurons linked to the routes of transmission of pain, although bronchial epithelium, gastrointestinal tract, nasal epithelial cells, and endothelial cells have also been shown to express the channel,[@b21-bctt-10-161],[@b22-bctt-10-161] in particular, in the context of inflammatory responses. Constitutive expression in nociceptive neurons follows a classical pattern of TRPV1 localization at the plasma membrane strengthening its role as a pain modulator. Differently, the inducible expression exhibits a special subcellular distribution that has not yet been fully described. It is expected that a better understanding of this inducible behavior of TRPV1 will provide some explanations on the homeostatic mechanisms developed by tumors achieving higher malignancy related to TRPV1 strategies.

The TRP channels are highly expressed in different types of cancers,[@b23-bctt-10-161] and some authors have suggested its role as a therapeutic target in breast cancer.[@b24-bctt-10-161] In tumor cells, TRP channels may contribute to cancer progression through changing the activity of signaling pathways associated with variation in intracellular Ca2+ levels, particularly by modifying the cell proliferation and migration.[@b25-bctt-10-161],[@b26-bctt-10-161] The transcriptional regulation of TRP channels under hormonal control is the main studied mechanism in hormone-dependent cancers, such as prostate and breast cancers.[@b7-bctt-10-161]

In the present study, individuals with nonclassical patterns of TRPV1 expression showed lower survival rates than the individuals with classical patterns. In addition, TRPV1 nonclassical aggregates were associated with the more aggressive St. Gallen subtypes, suggesting that breast cancer malignancy and progression could be related to altered turnover of the channel, possibly due to postransductional modifications. Further explorations are needed to elucidate whether these aggregates are causal or rather a consequence of the tumor behavior, though this phenomenon seems to reflect changes in important cell functions that depend on the availability of TRP channels at the plasma membrane. Indeed, dynamic changes in the availability of TRP channels at the plasma membrane have been put forward as potentially important regulatory mechanisms of TRP channel function in vivo.[@b27-bctt-10-161] Accumulation of the channel in Golgi complex may have functional implications. The intracellular sequestration of TRPV1 in neurons has been associated with the predominance of the monomeric form of channel, instead of the tetrameric form,[@b28-bctt-10-161] which may result in accumulates of nonfunctional forms of the channel. We interpret the lack of expression of the channel in the nonclassical category as due to the "abduction" of TRPV1 by the endomembrane system, as an intent to optimize cellular performances in stress conditions imposed by the tumor environment.

Estrogens have been demonstrated to exert transcriptional regulation of TRPV6,[@b7-bctt-10-161] in addition to their implication in modulating nociception through TRPV1 receptor.[@b29-bctt-10-161] The immunohistochemical expression of TRPV1 in biopsies of breast cancer has not been reported before, but the overexpression of the channel in cell lines of this type of cancer has been demonstrated,[@b9-bctt-10-161],[@b10-bctt-10-161],[@b30-bctt-10-161] similar to another channel of the same family, TRPV6, which is modified by estradiol/ progesterone and associated with proliferation of neoplastic cells.[@b31-bctt-10-161]

Our results indicate a dose-dependent relationship between the expression of TRPV1 and estrogens in cells that express ERα. In addition to the abundance of TRPV1, increasing doses of 17β-estradiol induced an increased concentration of the channel surrounding the nucleus, in relation to the ER/Golgi system, which might reflect strategies that favor the survival of tumor cells and may predict their progression to more malignant states. Therefore, it is likely that estrogen-dependent perinuclear accumulation of TRPV1 in breast cancer tumors can indicate some stationary state that confers comfortable survival conditions to the tumor and worsened prognosis to host individuals.

These observations put the focus on modulators of TRPV1 channels turnover as potential pharmacological targets in cancer subtypes and/or tumors expressing mainly nonclassical patterns of TRPV1. Nevertheless, until the nonclassical pattern is better characterized, the conductive form of TRPV1 in classical membrane localization offers a possible target that merits clinical exploration: sensitizing tumors with agonists as capsaicin may have favorable therapeutic effects on breast cancer, via the regulation of calcium homeostasis and mitochondrial activity,[@b8-bctt-10-161],[@b10-bctt-10-161],[@b23-bctt-10-161],[@b32-bctt-10-161] thus controlling the proliferation, apoptosis, and migration[@b9-bctt-10-161],[@b33-bctt-10-161],[@b34-bctt-10-161] of tumor cells. As an optimistic perspective, we hope to extend our analytic strategies for anticipating the tumor behavior focusing on understanding the role of TRPV1 subcellular distribution during the cancer progression.

Conclusion
==========

The intracellular TRPV1 aggregates in breast carcinoma are associated with particular biological behavior. Of clinical relevance, the expression of the nonclassical pattern is associated with worse prognosis and lower survival, suggesting that TRPV1 could be a therapeutic target for the most aggressive St. Gallen breast cancer subtypes. If confirmed in larger samples, the strength of our findings could introduce new criteria in the classification of breast cancer patients and inspire personalized therapeutic approaches based on homeostatic attack of tumor diseases.
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![Transcription and subcellular distribution of TRPV1 in MDA-MB-231 and MCF-7 cell lines.\
**Notes:** (**A**) TRPV1 mRNA expression in MDA-MB-231 and MCF-7 by qPCR did not reveal any statistical difference. (**B**) Different abundance and distribution of TRPV1 in MDA-MB-231 and MCF-7. Image magnification: images was obtained in 100· (optical). After analysis process, digital magnification was 1.25·. (**C**) Colocalization analysis results. In MDA-MB-231, most of TRPV1 protein followed the same subcellular distribution as the ER, whereas the classical pattern in MCF-7 did not colocalize with the ER/Golgi mark. (**D**) MDA-MB-231 and MCF-7 exhibited different expressions of ERs. In MDA-MB-231, qPCR experiments showed expression of ERβ only, whereas MCF-7 expressed both ERα and ERβ (*P*\<0.05). (**E**) The transcription of TRPV1 in MCF-7 was induced by estradiol and blocked by the antagonist of ER ICI 182780. \**p*\>0.05. (**F**) In MCF-7, TRPV1 did not present significant colocalization with any of the masks automatically generated, ie, plasma membrane, cytosol, and nucleus. This pattern can be classified as classical. On the other hand, MDA-MB-231 colocalizes more proteins in the cytosol mask, this pattern being classified as nonclassical.\
**Abbreviation:** qPCR, quantitative PCR.](bctt-10-161Fig1){#f1-bctt-10-161}

![Nonclassical pattern of TRPV1 identifies higher malignancy breast carcinomas.\
**Notes:** (**A**) The immunofluorescence of C-TRPV1 and N-TRPV1 antibodies confirmed the expression of TRPV1 in breast cancer, with a diffuse expression pattern. (**B**) The immunohistochemical detection of TRPV1 shows a classical pattern at the plasma membrane and cytosol, and a nonclassical pattern with aggregates of TRPV1 at the ER/Golgi and/or a relatively diffuse distribution of the channel at the surrounding cytosol. (**C**) The classical TRPV1 pattern was more frequent in lower malignancy St. Gallen subtypes luminal A + luminal B compared to the most aggressive subtypes Her 2 + triple negative. (**D**) Survival curves according to the pattern of TRPV1 subcellular distribution.](bctt-10-161Fig2){#f2-bctt-10-161}

###### 

Clinical parameters according to TRPV1 expression categories

  Parameters                     Classical   Nonclassical   *P*-value                                          Total
  ------------------------------ ----------- -------------- -------------------------------------------------- -------
                                                                                                               
  T stage                                                                                                      
   T1/T2                         18 (62.0)   11 (37.9)      0.614                                              29
   T3/T4                         3 (75)      1 (25)         0.741                                              4
  N stage                                                                                                      
   N1                            10 (66.6)   5 (33.3)       0.741                                              15
   N2--3                         11 (61.1)   7 (38.8)       0.029[a](#tfn1-bctt-10-161){ref-type="table-fn"}   18
  Clinical stage                                                                                               
   I/II                          10 (66.6)   5 (33.3)       0.060                                              15
   III/IV                        11 (61.1)   7 (38.8)                                                          18
  St. Gallen                                                                                                   
   Lower malignancy (LA+LB)      19 (73.1)   7 (26.9)                                                          26
   Higher malignancy (HER2+TN)   2 (28.5)    5 (71.5)                                                          7
  Death                                                                                                        
   No                            17 (73.9)   6 (26.0)                                                          23
   Yes                           4 (40.0)    6 (60.0)                                                          10
  Total                          21          12                                                                33

**Note:**

Significant association of the frequency of nonclassical pattern with higher malignancy St. Gallen subtypes.
